News & articles

Novartis will collaborate with Incyte on the further development of two of Incyte Corp.’s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process. If approved, this will be the first FDA approved treatment for myelfibrosis. For more information: Press release BioWorld

By Mike Nagle 24/05/2007 – At a time when pharma productivity is declining, anticancer specialists Exelixis has started more Phase I clinical trials this year than any other company. The US biotech has today filed an Investigational New Drug (IND) application to US regulators at the Food and Drug Administration (FDA). It is the company’s… Read More »EXELIXIS WINNING PHASE I RACE

Society’s Prestigious Specialized Center of Research Program Hits $159 Million Mark WHITE PLAINS, N.Y., Oct. 23 /PRNewswire/ — The Leukemia & Lymphoma Society today announced it has awarded four new Specialized Center of Research (SCOR) grants, the Society’s most ambitious and synergistic research initiative, bringing the program’s total funding to $159 million since its inception… Read More »RESEARCHERS ADVANCING BLOOD CANCER THERAPIES RECEIVE $42.75 MILLION IN GRANTS FROM THE LEUKEMIA & LYMPHOMA SOCIETY

By Lois M. CollinsDeseret Morning News The University of Utah will receive more than $2 million over five years to investigate the causes of several incurable blood disorders. The money is part of a $19.6 million grant from the National Cancer Institute to the Myeloproliferative Disorders Research Consortium, a group of researchers from eight institutions… Read More »UNIVERSITY OF UTAH TO INVESTIGATE BLOOD DISORDERS

By: Dr. Gary Gilliland, Harvard Medical School Many patients with polycythemia vera (PV), essential thrombocythemia (ET) or myelofibrosis (MF) have the JAK2V617F mutation. This finding has reinvigorated and revolutionized research on these MPDs. We now understand that there is a cell growth pathway that is activated by the JAK2V617F mutations, call the JAK-STAT pathway. This… Read More »DISCOVERY OF A NEW MUTATION IN JAK2V617F NEGATIVE MYELOFIBROSIS PATIENTS

By Donna Young Washington Editor Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology’s annual meeting in Atlanta. In a retrospective study examining 30 years of records of 311 patients with myelofibrosis,… Read More »STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME

Thursday October 19, 7:25 pm ET Approvals Represent First Time a Regulatory Authority has Simultaneously Approved One Targeted Medicine for Five DisordersNow Approved for the Solid Tumor Cancer, Dermatofibrosarcoma ProtuberansUS Approval Also Granted for Treatment of Four Blood Diseases:Multiple Approvals in Only Five Years Highlight new Approach of Developing Treatments Based on Common Molecular Pathways… Read More »GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS

Thursday, October 19, 2006 · Last updated 3:30 p.m. PTTHE ASSOCIATED PRESS WASHINGTON — A Novartis AG cancer drug has won expanded federal approval to treat five rare and potentially life-threatening diseases, the company said Thursday. Gleevec, also called imatinib mesylate, may now be prescribed to treat dermatofibrosarcoma protuberans tumors, as well as four blood… Read More »NOVARTIS DRUG

* Excerpts from UIC news release of September 6, 2006, announcing the NCI grant to the MPD International Research Consortium A $19.6 million National Cancer Institute grant has been awarded to the University of Illinois at Chicago College of Medicine to advance basic and clinical research for incurable blood disorders. It is the largest grant… Read More »UIC RECEIVES $20 MILLION NCI GRANT TO RESEARCH BLOOD DISORDERS

Thursday, July 20, 2006 Belmont resident Al Bolea lost his gallant seven-year fight against myelofibrosis at age 47. Bolea was a member of the Charles River Wheelmen (CRW) cycling club. Riding on his own, he dominated the hills on rides throughout Massachusetts and New England. Yet as a leader of CRW’s Wednesday night ride throughout… Read More »BIKE RIDE FUND-RAISER IN MEMORY OF BELMONT CYCLIST